The Claim
Patients with cirrhosis exhibit impaired melatonin pharmacokinetics characterized by reduced endogenous production and decreased elimination, resulting in an altered systemic melatonin profile.
What the research says
Supports is higher
Support is ahead, but a single strong opposing study can change this.
These are independent scores, not a percentage. Higher-grade studies count more, so a single strong opposing study can outweigh several weaker ones.
People with severe liver disease (cirrhosis) have trouble making and clearing melatonin, which changes how much of this sleep hormone is in their bodies. This happens because the damaged liver can't process or produce the hormone properly.
See the scientific wording
Individuals with cirrhosis exhibit both decreased melatonin elimination and reduced daily endogenous production, indicating a dual impairment in melatonin pharmacokinetics. This combined reduction in synthesis and clearance fundamentally alters the overall melatonin profile in patients with advanced liver disease. This finding is from the abstract summary - full study details were not available.
What the research says
1 studyStudy: Pharmacokinetics of melatonin in man: first pass hepatic metabolism.
The study shows that people with severe liver disease process and naturally make less of the sleep hormone melatonin. This double drop in both production and breakdown changes how melatonin works in their bodies.
Score breakdown, mechanism chain, raw evidence, ideal studies needed & 1 supporting studies
Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.